Oracle Runs

Will the results be positive?

Trial ongoing per sponsor site and ClinicalTrials.gov as of April 2026, with estimated primary completion Feb 2026. No public topline results, readout, or efficacy interpretation found in searches despite expected interim in H1 2024. Evidence incomplete, no clear positive/negative framing.

Will the results be positive?

Trial (NCT05776004) is ongoing (Active, Not Recruiting; primary completion Feb 2026). No public topline readout, results posting, or efficacy interpretation found on clinicaltrials.gov, sponsor site, or news. No sources frame this exact Phase 2 as positive or negative.

Will the results be positive?

ClinicalTrials.gov still lists this study as active not recruiting with no posted results, so there is not yet a clear public positive or negative trial readout.

Will the results be positive?

No trial-specific efficacy readout was found. ClinicalTrials.gov shows NCT05776004 was still active/not recruiting with no results posted as of January 28, 2026, and Eagle’s 2025 filing still described CAL02 as in Phase 2 development. Without a public readout, positive vs negative cannot be determined.

Will the results be positive?

No clear overall positive/negative Phase 2 readout is publicly available. Eagle disclosed only a 50% interim analysis: positive safety and “encouraging efficacy trends” in subsets, but enrollment was suspended for protocol modifications and strategic review. That is interim and incomplete, not a definitive trial-level outcome.